These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16873827)

  • 21. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study.
    Pearson ER; Donnelly LA; Kimber C; Whitley A; Doney AS; McCarthy MI; Hattersley AT; Morris AD; Palmer CN
    Diabetes; 2007 Aug; 56(8):2178-82. PubMed ID: 17519421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical basis for contemporary classification and management of the diabetes syndrome.
    Skillman TG
    Trans Assoc Life Insur Med Dir Am; 1984; 66():44-56. PubMed ID: 6397899
    [No Abstract]   [Full Text] [Related]  

  • 23. [Pharmacologic treatment of diabetes].
    De Montigny P; Clerc C; Descarpentries C
    Perspect Infirm; 2006; 4(2):30-4. PubMed ID: 17184094
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus.
    Kawamori R; Eliaschewitz FG; Takayama H; Hayashida CY
    Diabetes Res Clin Pract; 2008 Jan; 79(1):97-102. PubMed ID: 17919763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Chronic kidney disease and antidiabetic treatment].
    Berwert L; Teta D; Zanchi A
    Rev Med Suisse; 2007 Mar; 3(101):598-604. PubMed ID: 17436798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Follow-up of intensive glucose control in type 2 diabetes.
    Petrie JR
    N Engl J Med; 2009 Jan; 360(4):416-7; author reply 418. PubMed ID: 19172672
    [No Abstract]   [Full Text] [Related]  

  • 27. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas?
    Al-Ozairi E; Sibal L; Home P
    Diabetes Care; 2007 Jun; 30(6):1677-80. PubMed ID: 17351288
    [No Abstract]   [Full Text] [Related]  

  • 28. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
    Holstein A; Hahn M; Stumvoll M; Kovacs P
    Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follow-up of intensive glucose control in type 2 diabetes.
    Mühlhauser I
    N Engl J Med; 2009 Jan; 360(4):417; author reply 418. PubMed ID: 19172674
    [No Abstract]   [Full Text] [Related]  

  • 30. [Pharmacodynamics of second-generation sulfonylureas: dose-effect curve of gliquidone in type II diabetics].
    Procacci V; Giovine A; Roberto MG; Ronchi AM; Lasorsa G; Vendemiale G; Stufano N; Altomare E
    Boll Soc Ital Biol Sper; 1988 Aug; 64(8):731-8. PubMed ID: 3214573
    [No Abstract]   [Full Text] [Related]  

  • 31. Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
    Inzucchi SE
    Endocrinol Metab Clin North Am; 2007 Dec; 36 Suppl 2 Incretin():2-17. PubMed ID: 18405144
    [No Abstract]   [Full Text] [Related]  

  • 32. Drugs for type 2 diabetes.
    Treat Guidel Med Lett; 2008 Jul; 6(71):47-54. PubMed ID: 18583949
    [No Abstract]   [Full Text] [Related]  

  • 33. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-monitoring of blood glucose: a test for patients or health-care professionals?
    Bhatnagar D
    Ann Clin Biochem; 2009 Jul; 46(Pt 4):271-2. PubMed ID: 19654101
    [No Abstract]   [Full Text] [Related]  

  • 35. Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Bell DS
    Acta Diabetol; 2009 Jun; 46(2):155; author reply 157. PubMed ID: 19300899
    [No Abstract]   [Full Text] [Related]  

  • 36. Combined insulin and oral sulfonylureas--how sweet it isn't!
    Ponte CD
    DICP; 1990 Dec; 24(12):1234-5. PubMed ID: 2089839
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes.
    Bermúdez V; Cano R; Cano C; Bermúdez F; Leal E; Acosta K; Mengual E; Arraiz N; Briceño C; Gómez J; Bustamante M; Aparicio D; Cabrera M; Valdelamar L; Rodriguez M; Manuel V; Hernández R
    Am J Ther; 2008; 15(4):409-16. PubMed ID: 18645347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term pioglitazone therapy improves arterial stiffness in patients with type 2 diabetes mellitus.
    Harashima K; Hayashi J; Miwa T; Tsunoda T
    Metabolism; 2009 Jun; 58(6):739-45. PubMed ID: 19446110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory cytokines in insulin-treated patients with type 2 diabetes.
    Mavridis G; Souliou E; Diza E; Symeonidis G; Pastore F; Vassiliou AM; Karamitsos D
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):471-6. PubMed ID: 17976964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.